Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Diagnostic
- Drugs
- Biotechnology
- Medical
- Cancer
- Surgical
- Genome
- DNA
- Disease
- Test/Monitoring
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26962
License Grant
The University hereby grants to Licensee exclusive, worldwide licenses under Regents’ Patent Rights within the Field of Interest to make, have made, use, sell, distribute, and lease machines, articles of manufacture, and compositions-of-matter and to perform processes and have others perform processes.
License Property
The Invention has utility for the detection of chromosome abnormalities.
Patent Rights shall mean all U.S. and foreign patents and patent applications related to Pending U.S. Patent Application Serial No. 819,314 & 6-937,793 entitled Method and Compositions for Chromosome-Specific Staining ;.Pending U.S. Patent Application Serial No. 6-934,188 entitled Method of Preparing and Applying Single Stranded DNA Probes to Double Stranded Target DNAs; Any U.S. Patent Application based on subject matter described in UC Case Number 87-095-1 (renumbered UC Case Number 85-157-4) entitled Method for Determining Aneuploidy in Fetal Cells from Maternal Blood Samples.
Field of Use
'Field of Interest' shall mean relating to analytical, research, and diagnostic applications of technology based on chromosomal staining, marking, and labeling. Field of Interest shall specifically exclude therapies and treatments derived from analytical, research, and diagnostic applications.
IPSCIO Record ID: 159305
License Grant
The Great Britain University grants to Licensee and its Affiliates a worldwide exclusive license under its Patent Rights, Technology, and Tangible Technical Materials to make, have made, import, use, offer to sell, or sell Licensed Subject Matter during the Term of this Agreement.
License Property
Licensed Subject Matter shall mean Licensed Patent Product, Patent Rights, Technology, and Tangible Technical Materials for in-vitro diagnostic assays, using labeled nucleic acid probes.
UK Patent Application Number 9704054.7 entitled 'Chromosome-specific Paint Probes'
The University owns Technology and Tangible Technical Materials related to Assays to Detect and Analyze Chromosomal Aberrations in various species using labeled DNA from a related species as a set of probes and, the United Kingdom patent for Chromosome-specific Paint Probes.
Based upon a novel method developed by scientists at the University, the Company's RxFISH(TM) assay develops a unique fluorescent color banding pattern for human chromosomes that is then analyzed by the CytoVision software.
Field of Use
The field is in-vitro diagnostic assays, using labeled nucleic acid probes. The Licensee is in the business of automated clinical analysis systems used by cytogenetic laboratories for prenatal and other genetic testing applications.
IPSCIO Record ID: 260378
License Grant
Licensor grants a non-exclusive license, without the right to grant or authorize sublicenses, under the Licensed Patent Rights to develop and perform the Services solely at the Facilities, and to use, and offer for sale and sell the Services to Third Parties solely in the Territory.
License Property
Licensed Patent Rights shall mean, collectively, Licensors rights in all patent applications, including provisional patent applications, heretofore or hereafter filed in the Territory; all patents that have issued or in the future issue in the Territory from any of such patent applications, including without limitation utility models, design patents and certificates of invention; and, all divisionals, continuations, continuations-in-part, substitutions, reissues, renewals, extensions, restorations or additions to any such patent applications and patents, in each case that claim, and only to the extent they claim, compositions, uses, methods, equipment, devices and other technology for the use of cell-free fetal nucleic acids from biological samples, including plasma, serum, whole blood and urine, obtained from pregnant women for prenatal diagnostic testing by whole genome massively parallel sequencing, used in the performance of the MaterniT21 PLUS Test by Licensors Laboratories as of the Effective Date, or any improvements to such test; provided, however, that the Licensed Patent Rights shall exclude any of the foregoing licensed by a University to Licensor under another agreement.
MatemiT21 PLUS Test shall mean the laboratory-developed test for the non-invasive testing of a plasma sample from a pregnant woman for the detection and diagnosis of prenatal aneuploidy and/or fetal abnormalities by use of cell-free fetal nucleic acids, currently known as the MatemiT21 PLUS test, as performed by Licensors Laboratories.
Field of Use
The Field shall mean the non-invasive detection and diagnosis of prenatal aneuploidy and fetal abnormalities by use of cell-free fetal nucleic acids from biological samples, including plasma, serum, whole blood and urine, obtained from pregnant women.
The MaterniT® 21 PLUS test analyzes genetic information that enters your bloodstream from the placenta. It analyzes the amount of chromosome 21 in fetal DNA picked up from the maternal blood sample. It can detect an increased amount of chromosome 21 material which is associated with trisomy 21 (Down syndrome). It is completely non-invasive as it only involves a blood sample from the mother.
IPSCIO Record ID: 243457
License Grant
University hereby grants to Licensee an exclusive license under the licensed patents for the terms defined to make, have made, use, sell and practice the invention in the countries where the licensed patents are effective or applications are pending, subject to rights required to be granted to the U.S. Government. Notwithstanding the preceding, University shall retain the right to make, use and practice the invention for itself for research purposes only.
University grants to Licensee a non-exclusive to make, practice and use the know-how worldwide for the term defined.
University grants to Licensee the right to grant sublicenses to third parties under terms and conditions at least equal to those contained herein provided that the terms of this agreement are included wherever applicable in such sublicenses. Licensees right to sublicense hereunder shall be exclusive to it and such sublicenses shall be coterminable with this agreement and the license granted to Licensee hereunder.
License Property
The Invention shall mean methods, processes and related reagents described in U.S. Patent Application Serial Number 271.609.
The Inventors have discovered new methods for the delineation of individual human chromosomes in metaphase and interphase cells by IN SITU suppression hybridization and have filed a patent application of like title thereon at Licensees expense (the Invention).
Licensed products or services shall mean any process, method or reagent or other product or service covered within the scope of a valid claim of the licensed patents and any product produced or manufactured using any such process, method or reagent and any service performed using any such process, method or reagent.
Field of Use
The subject invention relates to a method of detecting, identifying and/or quantitating selected individual chromsomes in mammalian mitotic or interphase cells, by means of chromosomal in situ suppression (CISS) hybridization and its use in analyzing cells for the occurrence of chromosomes, chromosome fragments, or chromosome aberrations, such as those associated with a condition or disease.
In the method of the present invention, chromosome-specific probes (DNA or RNA) are combined with a sample to be analyzed, in such a manner that an individual chromosome(s) of interest is labeled and the complex spectrum of sequences which comprise the chromosome can be detected. The probes used in the present method are of high genetic complexity and can be appropriately-selected cloned DNA or RNA fragments, used individually or in pools, or chromosome library DNA.
IPSCIO Record ID: 27123
License Grant
The University hereby grants to the Licensee a world-wide license under the University Patent Rights to make have made, use, and sell Licensed Products and to practice Licensed Method.
The University also grants to the Licensee the right to issue sublicenses to third parties to make, have made, use, and sell Licensed Products and to practice Licensed Method, provided the Licensee has current exclusive rights thereto under this Agreement.
License Property
Patent Rights means patent rights to any subject matter claimed in or covered by any of the following Pending U.S. Patent Application serial no. 191,852 entitled a Detection of Mycoplasma by DNA Hybridization.
Mycoplasma is a genus of bacteria that lack a cell wall.[1] Without a cell wall, they are unaffected by many common antibiotics such as penicillin or other beta-lactam antibiotics that target cell wall synthesis. They can be parasitic or saprotrophic. Mycoplasma infection is respiratory illness caused by Mycoplasma pneumoniae, a microscopic organism related to bacteria.
IPSCIO Record ID: 1741
License Grant
The Company entered into an agreement to acquire an invention for the use of certain antibodies in the identification of fetal cells from maternal blood. Licensor assigns all of his Trade Secret Rights and Patent Rights in the Invention to Licensee.
License Property
Licensor owns certain intellectual property and trade secret rights in the concept and techniques of using anti-embryonic hemoglobin antibodies in the process of identifying fetal cells in the maternal blood
The Invention shall mean the concept and techniques of using anti-embryonic hemoglobin antibodies, directed against either or both of the epsilon or zeta chains, in the process of identifying fetal cells in the maternal blood.
Trade Secret Rights shall mean any and all information relating to the Invention. The Product shall mean a test or product for identifying fetal cells in the maternal blood which utilizes the Invention. The term Product shall include a combination product or test which utilizes the Invention and also utilizes Licensee's enrichment technology. The term Product shall not include Licensee's instrumentation technology related to the fetal cells or maternal blood and, to the extent sold separately, shall not include Licensee's tests or products relating to nucleic acid probes for identification of fetal nucleic acids, and Licensee's enrichment technology to be used on cells other than fetal cells.
Field of Use
Licensee is in the business of surgical and medical instruments and apparatus.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
